TY - JOUR
T1 - Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer
T2 - Association with tumor grade and CA-125
AU - Kazeto, Hideo
AU - Nomura, Seiji
AU - Ito, Norio
AU - Ito, Tomomi
AU - Watanabe, Yoshiteru
AU - Kajiyama, Hiroaki
AU - Shibata, Kiyosumi
AU - Ino, Kazuhiko
AU - Tamakoshi, Koji
AU - Hattori, Akira
AU - Kikkawa, Fumitaka
AU - Nagasaka, Tetsuro
AU - Tsujimoto, Masafumi
AU - Mizutani, Shigehiko
PY - 2003
Y1 - 2003
N2 - Adipocyte-derived leucine aminopeptidase (A-LAP) is a novel zinc-metallopeptidase involved in angiotensin II (AngII) metabolism, cell migration and antigen presentation. These functions are implicated in the progression of cancer, whereas A-LAP expression and involvement have not been studied in any type of cancer. We investigated the expression of A-LAP in endometrial cancer as well as its association with angiogenesis and clinicopathological features. Immunohistochemical staining of 58 endometrial endometrioid adenocarcinoma specimens revealed that 37 were A-LAP immunoreactive. We also found that A-LAP staining correlated with histological tumor grade in a significant and reverse manner. In addition, serum CA-125 levels in patients with A-LAP positive cancers were significantly higher. However, contrary to our hypothesis that A-LAP suppresses angiogenic activity via AngII metabolism, A-LAP expression was not associated with the microvessel count determined by CD34 immunostaining. Our results suggest that A-LAP is involved in endometrial cancer cell growth and differentiation. However, further studies, especially of the biological roles of A-LAP, are required to confirm this notion.
AB - Adipocyte-derived leucine aminopeptidase (A-LAP) is a novel zinc-metallopeptidase involved in angiotensin II (AngII) metabolism, cell migration and antigen presentation. These functions are implicated in the progression of cancer, whereas A-LAP expression and involvement have not been studied in any type of cancer. We investigated the expression of A-LAP in endometrial cancer as well as its association with angiogenesis and clinicopathological features. Immunohistochemical staining of 58 endometrial endometrioid adenocarcinoma specimens revealed that 37 were A-LAP immunoreactive. We also found that A-LAP staining correlated with histological tumor grade in a significant and reverse manner. In addition, serum CA-125 levels in patients with A-LAP positive cancers were significantly higher. However, contrary to our hypothesis that A-LAP suppresses angiogenic activity via AngII metabolism, A-LAP expression was not associated with the microvessel count determined by CD34 immunostaining. Our results suggest that A-LAP is involved in endometrial cancer cell growth and differentiation. However, further studies, especially of the biological roles of A-LAP, are required to confirm this notion.
UR - http://www.scopus.com/inward/record.url?scp=0345059335&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345059335&partnerID=8YFLogxK
U2 - 10.1159/000074431
DO - 10.1159/000074431
M3 - Article
C2 - 14654715
AN - SCOPUS:0345059335
VL - 24
SP - 203
EP - 208
JO - Oncodevelopmental Biology and Medicine
JF - Oncodevelopmental Biology and Medicine
SN - 1010-4283
IS - 4
ER -